IDH1 and acute myeloid leukemia: Specific gain-of-function mutations in IDH-1 lead to the production of D-2-hydroxyglutarate, a metabolite implicated in the pathogenesis of various cancers, including glioma, acute myeloid leukemia, and iCCA, which is found in 13–25% of cases [24].